See more : Hillman Solutions Corp. (HLMN) Income Statement Analysis – Financial Results
Complete financial analysis of Kymera Therapeutics, Inc. (KYMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kymera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jenn Feng Industrial Co., Ltd. (1538.TW) Income Statement Analysis – Financial Results
- Rosetta Genomics Ltd. (ROSGQ) Income Statement Analysis – Financial Results
- Telefónica, S.A. (TEFOF) Income Statement Analysis – Financial Results
- Jiangsu Hanvo Safety Product Co., Ltd. (300952.SZ) Income Statement Analysis – Financial Results
- Mitesco, Inc. (MITI) Income Statement Analysis – Financial Results
Kymera Therapeutics, Inc. (KYMR)
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0.00 |
| Cost of Revenue | 189.08M | 2.98M | 2.40M | 62.11M | 825.00K | 205.00K |
| Gross Profit | -110.49M | 43.85M | 70.44M | -28.07M | 2.11M | -205.00K |
| Gross Profit Ratio | -140.59% | 93.64% | 96.71% | -82.48% | 71.88% | 0.00% |
| Research & Development | 189.08M | 164.25M | 137.02M | 62.11M | 37.16M | 17.68M |
| General & Administrative | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Cost & Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Interest Income | 18.76M | 6.62M | 488.00K | 826.00K | 1.01M | 0.00 |
| Interest Expense | 196.00K | 176.00K | 175.00K | 115.00K | 46.00K | 16.00K |
| Depreciation & Amortization | 3.57M | 2.98M | 2.40M | 1.76M | 825.00K | 205.00K |
| EBITDA | -143.20M | -151.66M | -97.65M | -43.72M | -40.38M | -21.25M |
| EBITDA Ratio | -182.21% | -330.23% | -137.36% | -133.63% | -1,376.11% | 0.00% |
| Operating Income | -165.53M | -161.26M | -100.53M | -46.30M | -42.21M | -21.45M |
| Operating Income Ratio | -210.62% | -344.37% | -138.03% | -136.05% | -1,438.48% | 0.00% |
| Total Other Income/Expenses | 18.57M | 6.45M | 313.00K | 711.00K | 959.00K | -16.00K |
| Income Before Tax | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Income Before Tax Ratio | -186.99% | -330.60% | -137.60% | -133.96% | -1,405.79% | 0.00% |
| Income Tax Expense | 0.00 | -2.98M | -2.22M | -1.65M | 46.00K | 43.86K |
| Net Income | -146.96M | -151.83M | -98.00M | -43.95M | -41.29M | -21.47M |
| Net Income Ratio | -186.99% | -324.25% | -134.55% | -129.12% | -1,407.36% | 0.00% |
| EPS | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS Diluted | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| Weighted Avg Shares Out | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| Weighted Avg Shares Out (Dil) | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Source: https://incomestatements.info
Category: Stock Reports